TY - JOUR
T1 - Population pharmacokinetics and pharmacodynamics for treatment optimization in clinical oncology
AU - Zandvliet, Anthe S.
AU - Schellens, Jan H.M.
AU - Beijnen, Jos H.
AU - Huitema, Alwin D.R.
PY - 2008
Y1 - 2008
N2 - Population pharmacokinetic and pharmacodynamic analysis is an important tool to support optimal treatment in clinical oncology. The population approach is suitable to explain variability between patients and to establish relationships between drug exposure and a relevant pharmacodynamic parameter. This can facilitate the selection of dosing schedules, the development of strategies for dose individualization and the application of therapeutic drug monitoring of anticancer agents. This review discusses the role of population pharmacokinetics and pharmacodynamics in clinical oncology to enhance the efficiency of drug development and to support the development of safe and effective dosing regimens for optimal treatment of cancer patients. An overview of published population studies of investigational anticancer agents and established treatment regimens is presented.
AB - Population pharmacokinetic and pharmacodynamic analysis is an important tool to support optimal treatment in clinical oncology. The population approach is suitable to explain variability between patients and to establish relationships between drug exposure and a relevant pharmacodynamic parameter. This can facilitate the selection of dosing schedules, the development of strategies for dose individualization and the application of therapeutic drug monitoring of anticancer agents. This review discusses the role of population pharmacokinetics and pharmacodynamics in clinical oncology to enhance the efficiency of drug development and to support the development of safe and effective dosing regimens for optimal treatment of cancer patients. An overview of published population studies of investigational anticancer agents and established treatment regimens is presented.
KW - Alkylating agents, pharmacokinetics
KW - Antimetabolites, pharmacokinetics
KW - Antineoplastics, pharmacokinetics
KW - Aromatase inhibitors, pharmacokinetics
KW - Camptothecins, pharmacokinetics
KW - Cyclin dependent kinase 1 inhibitors, pharmacokinetics
UR - http://www.scopus.com/inward/record.url?scp=47049112936&partnerID=8YFLogxK
U2 - 10.2165/00003088-200847080-00001
DO - 10.2165/00003088-200847080-00001
M3 - Review article
C2 - 18611060
AN - SCOPUS:47049112936
SN - 0312-5963
VL - 47
SP - 487
EP - 513
JO - Clinical Pharmacokinetics
JF - Clinical Pharmacokinetics
IS - 8
ER -